Antibody
- Instrumentos
- Agitadores / Agit. Incubadores
- Orbitales
- Con Incubación
- Incubadores Gran Capacidad
- Lineales, Balanceo y 3D
- Incubadores Microplacas
- Para colocar en estufa
- Magnéticos
- Mezcladores /Roller /Rotatorios
- Agitadores de Paletas
- Jeio Tech Accesorios para Agitadores
- Benchmark Accesorios para Agitadores
- N-Biotek Accesorios para Agitadores
- Biosan Accesorios para Agitadores
- Labnet Int. Accesorios para Agitadores
- Vórtex
- Analisis Imagen, animales, plantas, geles
- Balanzas
- Baños Termostáticos
- Cabinas Flujo / Extraccion gases / PCR
- Centrifugas
- Detectores de Radioactividad
- Electroforesis
- Electroquímica
- Equipos Microplacas
- Espectrofotometros
- Experimentacion Animal
- Hornos de Hibridacion
- Homogeneizadores
- Estufas / Equipos calor, frio
- Luminómetros de Tubos
- Microbiologia
- Pipetas / Dispensadores
- Pipetas Labnet Int. Monocanales Automaticos
- Pipetas HTL Monocanales Automáticas
- Pipeta Accumax Mono y Multicanales
- Pipetas Labnet Int. Multicanales
- Pipetas HTL Multicanales
- Pipetas Volumen Fijo
- Pipetas Electrónicas
- Dispensadores
- Dispensadores de Botella
- Pipetas Biosan Monocanales
- Pipetas Biosan Multicanales
- PCR / Tiempo Real (qPCR)l / Cicladores
- QPCR, Sistemas automaticos
- Sonicadores / Ultrasonidos
- Ultracongeladores
- Bombas Jeringa / Vacio / Osmoticas
- Ultracentrífugas
- Micro Array label free
- Contadores de Células
- Contenedores Criogenicos
- Producción agua ultrapura
- Electrospinning
- Agitadores / Agit. Incubadores
- Reactivos
- Consumibles
- Catálogos PDF
Antibody Hay 184 productos.
Eculizumab
Eculizumab is a first-in-class recombinant humanized monoclonal antibody targeting complement protein C5. C5, which can only recognize humans, cannot bind to C5 of other species.
Spesolimab
Spesolimab (BI 655130) is an anti-IL-36R antibody. IL-36 involves in immune system, as Spesolimab can be used for palmoplantar pustulosis (PPP) research. Spesolimab is associated with the reduction of biomarkers linked to innate, Th1/Th17, and neutrophilic pathways.
Eculizumab
Eculizumab is a first-in-class recombinant humanized monoclonal antibody targeting complement protein C5. C5, which can only recognize humans, cannot bind to C5 of other species.
Tafasitamab
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.
Tafasitamab
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.
Spesolimab
Spesolimab (BI 655130) is an anti-IL-36R antibody. IL-36 involves in immune system, as Spesolimab can be used for palmoplantar pustulosis (PPP) research. Spesolimab is associated with the reduction of biomarkers linked to innate, Th1/Th17, and neutrophilic pathways.
Eldelumab
Eldelumab (BMS-936557) is a humanised anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease.
Pepinemab
Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D.
Alirocumab
Alirocumab is a humanized IgG1 PCSK9 monoclonal antibody that can be used in the study of hypercholesterolemia.
Eldelumab
Eldelumab (BMS-936557) is a humanised anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease.
Abelacimab
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies.
